Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-cash Items (2020 - 2024)

Historic Non-cash Items for TScan Therapeutics (TCRX) over the last 5 years, with Q4 2024 value amounting to $24.0 million.

  • TScan Therapeutics' Non-cash Items fell 1512.84% to $24.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $24.0 million, marking a year-over-year decrease of 1512.84%. This contributed to the annual value of $24.0 million for FY2024, which is 1512.84% down from last year.
  • Per TScan Therapeutics' latest filing, its Non-cash Items stood at $24.0 million for Q4 2024, which was down 1512.84% from $28.3 million recorded in Q4 2023.
  • Over the past 5 years, TScan Therapeutics' Non-cash Items peaked at $28.3 million during Q4 2023, and registered a low of $2.1 million during Q4 2021.
  • For the 5-year period, TScan Therapeutics' Non-cash Items averaged around $12.6 million, with its median value being $10.6 million (2021).
  • Its Non-cash Items has fluctuated over the past 5 years, first crashed by 4419.58% in 2021, then soared by 51320.75% in 2022.
  • Over the past 5 years, TScan Therapeutics' Non-cash Items (Quarter) stood at $3.8 million in 2020, then crashed by 44.2% to $2.1 million in 2021, then surged by 513.21% to $13.0 million in 2022, then surged by 117.52% to $28.3 million in 2023, then dropped by 15.13% to $24.0 million in 2024.
  • Its Non-cash Items stands at $24.0 million for Q4 2024, versus $28.3 million for Q4 2023 and $13.0 million for Q4 2022.